Kiniksa Pharmaceuticals International (KNSA) FCF Margin (2021 - 2026)
Kiniksa Pharmaceuticals International (KNSA) posted FCF Margin of 23.38% for Q1 2026, down 11.87% on a QoQ basis from 26.53% in Q4 2025, and up 720.0% year-over-year from 2.85% in Q1 2025.
Kiniksa Pharmaceuticals International (KNSA) FCF Margin (2021 - 2026) Analysis & Trends
Kiniksa Pharmaceuticals International's FCF Margin history runs 6 years deep, the most recent figure standing at 23.38% for Q1 2026.
- Quarterly FCF Margin rose 720.0% year-over-year to 23.38% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 21.83% (up 1468.0% YoY) and the FY2025 annual result came in at 20.19%, up 1642.0% from the prior year.
- FCF Margin was 23.38% for Q1 2026 at Kiniksa Pharmaceuticals International, down from 26.53% in the prior quarter.
- Across five years, FCF Margin topped out at 62.57% in Q3 2022 and bottomed at 105.91% in Q1 2022.
- A 5-year average of 3.9% and a median of 7.78% in 2022 frame the typical range for FCF Margin.
- Annual changes were most pronounced in 2022 — FCF Margin jumped 46669 bps — and 2023, when it slumped 3726 bps.
- Kiniksa Pharmaceuticals International's FCF Margin stood at 7.78% in 2022, then jumped by 38 bps to 10.77% in 2023, then sank by 30 bps to 7.54% in 2024, then jumped by 252 bps to 26.53% in 2025, then retreated by 12 bps to 23.38% in 2026.
- Business Quant data shows KNSA's FCF Margin at 23.38% in Q1 2026, 26.53% in Q4 2025, and 17.01% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -5.22% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 12.86% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -5.35% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 46.54% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 9.93% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 17.73% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -2.77% |
| 10 | Kiniksa Pharmaceuticals International | 4.82 Bn | 4.36 Bn | 193.47 Mn | 23.38% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 23.38% |
| Dec 31, 2025 | 26.53% |
| Sep 30, 2025 | 17.01% |
| Jun 30, 2025 | 19.20% |
| Mar 31, 2025 | 16.18% |
| Dec 31, 2024 | 7.54% |
| Sep 30, 2024 | -2.01% |
| Jun 30, 2024 | 4.69% |
| Mar 31, 2024 | 4.86% |
| Dec 31, 2023 | 10.77% |
| Sep 30, 2023 | 25.31% |
| Jun 30, 2023 | -9.89% |
| Mar 31, 2023 | -2.07% |
| Dec 31, 2022 | 7.78% |
| Sep 30, 2022 | 62.57% |
| Jun 30, 2022 | -39.65% |
| Mar 31, 2022 | -105.91% |
| Dec 31, 2021 | -117.39% |
| Sep 30, 2021 | -234.76% |
| Jun 30, 2021 | -506.33% |